Articles tagged with Cancer Medication
Comprehensive exploration of living organisms, biological systems, and life processes across all scales from molecules to ecosystems. Encompasses cutting-edge research in biology, genetics, molecular biology, ecology, biochemistry, microbiology, botany, zoology, evolutionary biology, genomics, and biotechnology. Investigates cellular mechanisms, organism development, genetic inheritance, biodiversity conservation, metabolic processes, protein synthesis, DNA sequencing, CRISPR gene editing, stem cell research, and the fundamental principles governing all forms of life on Earth.
Comprehensive medical research, clinical studies, and healthcare sciences focused on disease prevention, diagnosis, and treatment. Encompasses clinical medicine, public health, pharmacology, epidemiology, medical specialties, disease mechanisms, therapeutic interventions, healthcare innovation, precision medicine, telemedicine, medical devices, drug development, clinical trials, patient care, mental health, nutrition science, health policy, and the application of medical science to improve human health, wellbeing, and quality of life across diverse populations.
Comprehensive investigation of human society, behavior, relationships, and social structures through systematic research and analysis. Encompasses psychology, sociology, anthropology, economics, political science, linguistics, education, demography, communications, and social research methodologies. Examines human cognition, social interactions, cultural phenomena, economic systems, political institutions, language and communication, educational processes, population dynamics, and the complex social, cultural, economic, and political forces shaping human societies, communities, and civilizations throughout history and across the contemporary world.
Fundamental study of the non-living natural world, matter, energy, and physical phenomena governing the universe. Encompasses physics, chemistry, earth sciences, atmospheric sciences, oceanography, materials science, and the investigation of physical laws, chemical reactions, geological processes, climate systems, and planetary dynamics. Explores everything from subatomic particles and quantum mechanics to planetary systems and cosmic phenomena, including energy transformations, molecular interactions, elemental properties, weather patterns, tectonic activity, and the fundamental forces and principles underlying the physical nature of reality.
Practical application of scientific knowledge and engineering principles to solve real-world problems and develop innovative technologies. Encompasses all engineering disciplines, technology development, computer science, artificial intelligence, environmental sciences, agriculture, materials applications, energy systems, and industrial innovation. Bridges theoretical research with tangible solutions for infrastructure, manufacturing, computing, communications, transportation, construction, sustainable development, and emerging technologies that advance human capabilities, improve quality of life, and address societal challenges through scientific innovation and technological progress.
Study of the practice, culture, infrastructure, and social dimensions of science itself. Addresses how science is conducted, organized, communicated, and integrated into society. Encompasses research funding mechanisms, scientific publishing systems, peer review processes, academic ethics, science policy, research institutions, scientific collaboration networks, science education, career development, research programs, scientific methods, science communication, and the sociology of scientific discovery. Examines the human, institutional, and cultural aspects of scientific enterprise, knowledge production, and the translation of research into societal benefit.
Comprehensive study of the universe beyond Earth, encompassing celestial objects, cosmic phenomena, and space exploration. Includes astronomy, astrophysics, planetary science, cosmology, space physics, astrobiology, and space technology. Investigates stars, galaxies, planets, moons, asteroids, comets, black holes, nebulae, exoplanets, dark matter, dark energy, cosmic microwave background, stellar evolution, planetary formation, space weather, solar system dynamics, the search for extraterrestrial life, and humanity's efforts to explore, understand, and unlock the mysteries of the cosmos through observation, theory, and space missions.
Comprehensive examination of tools, techniques, methodologies, and approaches used across scientific disciplines to conduct research, collect data, and analyze results. Encompasses experimental procedures, analytical methods, measurement techniques, instrumentation, imaging technologies, spectroscopic methods, laboratory protocols, observational studies, statistical analysis, computational methods, data visualization, quality control, and methodological innovations. Addresses the practical techniques and theoretical frameworks enabling scientists to investigate phenomena, test hypotheses, gather evidence, ensure reproducibility, and generate reliable knowledge through systematic, rigorous investigation across all areas of scientific inquiry.
Study of abstract structures, patterns, quantities, relationships, and logical reasoning through pure and applied mathematical disciplines. Encompasses algebra, calculus, geometry, topology, number theory, analysis, discrete mathematics, mathematical logic, set theory, probability, statistics, and computational mathematics. Investigates mathematical structures, theorems, proofs, algorithms, functions, equations, and the rigorous logical frameworks underlying quantitative reasoning. Provides the foundational language and tools for all scientific fields, enabling precise description of natural phenomena, modeling of complex systems, and the development of technologies across physics, engineering, computer science, economics, and all quantitative sciences.
Researchers found that a single dose of Taxol had induced significant testicular weight loss compared to the control group. However, an injection of AS101 a day before Taxol prevented this damage. The study suggests that immune reaction to treatment causes additional testicular damage.
Researchers found Sprycel to be extremely effective in combating Gleevec resistance, with a major cytogenetic response reported in 45% of chronic phase patients. The drug works by binding to mutant proteins and inhibiting tyrosine kinases, offering CML patients a new treatment option.
Dasatinib successfully circumvents Gleevec resistance in 68 of 84 patients, providing new options for CML treatment. The drug works in advanced stages of the disease and shows durable responses with no serious side effects.
A phase I clinical trial reveals nilotinib has a relatively favorable safety profile and demonstrates activity against drug-resistant CML, with notable improvements in chronic phase CML patients. However, the agent shows less activity in acute lymphoblastic leukemia patients and may require careful monitoring for cardiac events.
Researchers at UC Davis have identified a peptide that targets malignant lymphocytes, distinguishing it from healthy ones. The peptide, LLP2A, has the potential to be used as an imaging agent for patients with lymphoid cancers, offering a more targeted approach than existing monoclonal antibodies.
Researchers found that a new drug, imatinib, destroys the blood vessels that feed prostate cancer cells, preventing tumor growth and metastasis. In a mouse model, tumors were significantly reduced when treated with a combination of imatinib and chemotherapy.
Researchers discovered that overexpressing a gene called uPA in mammary cancer cells can delay tumor progression and inhibit the formation of new blood vessels, leading to slower tumor growth. The study also suggests that uPA expression may have anti-cancer effects by reducing angiogenesis and proliferation.
A study found that cancer drug ads are often difficult to read, prioritizing effectiveness over safety. The ads typically featured large text highlighting benefits, with side effects and risks presented in smaller font.
The St. Jude program in Brazil reduced abandonment rates from 16% to 0.6% and increased event-free survival from 32% to 63%, providing continuous care and psychosocial support to families. The program's success is a model for reducing disparities in cure rates between high- and low-income countries.
A Phase 3 trial shows Xcytrin significantly prolongs time to neurologic progression in patients with non-small cell lung cancer and brain metastases. Xcytrin, a texaphyrin-based drug, enhances cancer cell death when combined with radiation.
A new approach to improving cancer chemotherapy involves giving anticancer drugs basic properties, allowing them to accumulate in both normal and malignant cells. This approach may lead to more effective treatment with fewer side effects.
Studies have shown that glycerrhetinic acid and glycerrhizic acid, found in liquorice, preferentially accumulate in the liver and can target tumors effectively. This could lead to improved treatment outcomes with reduced toxic effects on other parts of the body.
Researchers have found a promising new treatment for children with metastatic Gastrointestinal Stromal Tumor (GIST) that is resistant to imatinib. The therapy, sunitinib, has shown significant decreases in tumor-related activity and complete remission in some patients.
A new study by Dr. Ramalingam found that adding the drug vorinostat to standard chemotherapy improved outcomes for patients with advanced non-small cell lung cancer, with partial responses in 11 patients and disease stabilization in 7 more. The recommended dose of 400mg daily for two weeks was well-tolerated.
A new combination therapy after surgery has improved survival rates for pancreatic cancer patients by 50%, increasing median survival from 16.9 to 20.6 months. The study found significant benefits for patients with pancreatic head adenocarcinoma, a type of cancer that affects the pancreas.
A phase-2 clinical trial found that Pfizer's oral drug, sunitinib malate, showed activity similar to other approved agents for non-small cell lung cancer, resulting in six confirmed partial responses and disease stabilization in 27 patients. The study also explored the effectiveness and safety of a continuous dosing strategy.
A five-year study confirms Gleevec's effectiveness in treating Gastrointestinal Stromal Tumor (GIST), with 84% of participants showing clinical improvement. The treatment has durable benefits, with two patients experiencing complete remission, despite some developing resistance.
Research reveals genetic variants in genes involved in anthracyclines' metabolism increase risk of congestive heart failure (CHF) in childhood cancer survivors. The study suggests personalized treatment plans may be developed using gene classification to reduce toxic side effects.
Apo2L/TRAIL, a new cancer drug, has shown activity in treating advanced cancers with minimal side effects. The agent selectively induces programmed cell death in cancer cells while sparing normal cells, offering hope for targeted treatment options.
A study led by Michael C. Heinrich, M.D., found that patients with gastrointestinal stromal tumor (GIST) responded differently to Sunitinib depending on their tumor's genetic abnormality. The research highlights the importance of personalized medicine in cancer treatment.
A five-year update from the IRIS Study Group shows excellent results for people with Chronic Myelogenous Leukemia (CML) treated with Gleevec, a targeted cancer therapy. Overall survival rates reach 89% at five years, with fewer than 1% of patients progressing to accelerated or blast crisis phases.
Researchers at UC Davis Cancer Center report a significant extension of survival in advanced lung cancer patients treated with bortezomib plus standard care. The median overall survival was 11 months, with one-year survival at 46%, offering promising results for this patient population.
Researchers have discovered a zinc finger protein that can be inhibited when exposed to a platinum complex, offering new hope for the development of targeted HIV and cancer therapies. This breakthrough could lead to more specific and effective treatments with reduced side effects.
Dan David Prize winners Dr. Mendelsohn and Dr. Schlessinger were recognized for their groundbreaking research on cancer treatment and signal transduction. Their work has led to the development of effective therapies and treatments for various forms of cancer.
A phase 3 clinical study found that nearly half of patients with advanced illness experienced laxation within four hours of receiving methylnaltrexone, and over 70% responded by the end of the first week. The treatment also showed no diminishment of analgesia due to medication.
The Lancet comments on the FDA's delay in approving Plan B, an emergency contraceptive. The agency's failure to make a decision undermines its credibility. The acting FDA commissioner is urged to move swiftly and show independence.
Researchers at Northwestern University have developed a new method to deliver antisense cancer drugs using gold nanoparticles, outperforming conventional agents. The nanoparticles improve stability, binding efficiency, and cellular uptake of the DNA, resulting in enhanced gene knockdown and lower toxicity.
Researchers engineered mice with mutated EGFR genes that can be turned on or off to study lung tumorigenesis and treatment responses. Mutations in EGFR drive lung tumors into regression by inhibiting the gene or turning it off.
The IU Cancer Center will attract top-tier scientists and physicians with the gift, enhancing its national reputation as a leader in cancer research and patient care. The center's research and clinical programs are expanding, and partnerships are increasing to achieve goals.
A study found that patients with rheumatoid arthritis treated with TNF-blocking antibodies are at a higher risk of developing cancer and serious infections. The drugs, which were previously thought to be safe, may interfere with the body's ability to fight off infection and cancer.
Scientists discover a new compound, PI-103, that effectively inhibits the spread of brain cancer by targeting two separate steps in the signaling pathway. This dual blockade proves to be safe and effective in slowing down cancer cell proliferation in mice with human glioma cells.
The National Institute of Standards and Technology (NIST) will develop a measurement assessment material for proteins, mimicking human plasma proteome complexity. This collaboration aims to evaluate existing proteomic technologies, develop new ones, and establish reliable measurement tools for cancer research.
Researchers successfully transplanted white blood cells from cancer-resistant mice into normal mice, eradicating existing and preventing lethal doses of new aggressive cancers. This breakthrough study demonstrates the potential for cancer-resistant-cell therapy to treat highly aggressive types of cancer.
Researchers have identified a stomach receptor for Helicobacter pylori, a common gut bacteria that causes peptic ulcers and gastric cancer. The discovery suggests that drugs targeting this receptor could prevent or treat these diseases.
Researchers found that inhibiting myosin light chain kinase with ML-7 induces cell suicide in breast and prostate cancer cells. Combination with etoposide treatment reduces tumor growth by 88.5% and 79.1%, offering new target for cancer therapies.
Fenretinide has been shown to reduce the risk of second breast cancers in young women, particularly those under 40. The study found a 38% reduction in second breast cancers in pre-menopausal women and halved the risk for women under 40.
A preliminary study found that combining chemotherapy with the arthritis drug etanercept increased tolerance to higher doses and reduced patient fatigue. The treatment blocks tumor necrosis factor, a substance promoting tumor growth instead of hindering it.
Dr. Horwitz's research on paclitaxel's mechanism of action led to its development and approval for treating various tumor types. She now focuses on overcoming drug resistance, a major challenge in cancer treatment.
Researchers create computer algorithms to verify connection between material delivery and fluid pressure, potentially increasing chemotherapy success rate. The method may be used before chemotherapy begins to determine if high fluid pressure could render treatment ineffective.
Researchers found that cancer treatment effectiveness is independent of tumor type, and varying levels of specific proteins determine drug response. This study suggests a new approach to treating cancer by selecting therapies tailored for individual patients instead of one-size-fits-all approaches.
Researchers discovered that p110 alpha controls insulin signals, frequently mutated in cancer, but mice with a single mutation showed no signs of developing diabetes. The findings have immediate implications for testing p110 alpha-specific inhibitors for human therapies.
Researchers have developed a nano-particle system that targets and kills cancer cells using a combination of paclitaxel and doxorubicin. This innovative approach overcomes the challenge of delivering multiple drugs to tumors efficiently.
Researchers have identified a potential new treatment for malignant gliomas using bortezomib, which targets the NF-kB pathway to induce cell death. This discovery builds on previous studies showing that selective estrogen receptor modulators (SERMs) can also induce cell death in brain cancers.
Researchers identify mutation in JAK2 signaling pathway, allowing cells to bypass normal red blood-cell production process. This discovery could lead to the development of targeted treatments that improve treatment outcomes for patients with PV disease.
Strobel's program will be an introductory science course with hands-on learning, challenging students to think like working scientists. Students will collect natural products, purify and analyze compounds, and test their potential benefits.
Researchers applied engineering tools to study cell decision-making in cancer and inflammatory diseases. The studies uncovered a surprising link between the two, suggesting new treatment approaches for debilitating conditions like rheumatoid arthritis.
Experts warn that non-compliance with treatment is a major issue among teenage cancer patients, who are at high risk due to poorer prognosis rates. Improving communication skills and addressing barriers such as family support and information overload can help increase adherence.
Experts warn that doctors must discuss future fertility with young cancer patients to provide truly informed consent. Current data indicate room for improvement in fertility counselling, with only 34% of patients receiving pre-treatment advice.
The UK's first Professor of Teenage and Young Adult Cancer emphasizes the need for improved communication and coordination among pediatricians, oncologists, and other healthcare professionals. Currently, TYA cancer patients often receive sub-standard treatment due to fragmented care.
Researchers have discovered a potential new treatment for breast cancer metastasis to bone, where 70% of patients develop bone metastases. The study found that osteoprotegerin inhibits RANKL, a protein promoting bone breakdown and cancer cell growth.
Researchers developed a nimesulide derivative that selectively inhibits aromatase production in breast cancer cells, reducing the risk of hormone-related side effects. This could lead to more targeted treatments for postmenopausal women with estrogen-dependent breast cancer.
A research team led by Bibiana Bielekova found that daclizumab increases the number of regulatory natural killer cells, which correlates with better treatment outcomes for MS patients. The study suggests that daclizumab may not damage the immune system but rather shifts its reaction from T-cells to natural killer cells.
AACR Public Service Awards recognize Sherry Lansing and Janet Woodcock's dedication to advancing cancer research. Lansing, former Paramount CEO, has raised millions for cancer research through her non-profit advocacy group Stop Cancer, while Woodcock, FDA deputy commissioner, streamlines cancer medicine oversight.
The guidelines aim to help physicians decide when to stop taking medications in older adults. They consider factors such as life expectancy, the time until benefits are realized, goals of care, and treatment targets.
Researchers at Virginia Tech have developed a new anticancer drug that targets DNA using cisplatin-like units. The supramolecular complexes combine light-absorbing PDT agents with the drug, allowing it to bind to cancer DNA and remain inert until activated by a light signal.
Tamoxifen, originally designed as an anti-oestrogen, has proven effective in cancer treatment and is now licensed for preventing breast cancer in high-risk women. Raloxifene, developed to treat osteoporosis, also demonstrates potential in reducing invasive breast cancer risk by 76% in postmenopausal women.
The American Association for Cancer Research (AACR) has conferred its highest honors to several scientists for their groundbreaking contributions to cancer research. Carlo Croce and Wiliam Kaelin received awards for their pioneering work in leukemia and lymphoma research, while Julian Adams was recognized for his discovery of the first...
The study found that patients receiving the combination of paclitaxel and bevacizumab had a significantly improved progression-free survival of 11.4 months, compared to 6.11 months with paclitaxel alone. This trend also suggested improved overall survival in patients treated with the new drug combination.
Researchers found that low-intensity electrical stimulation increased the uptake of doxorubicin in cancer cells, causing them to die even at low concentrations. This novel strategy could bypass multidrug resistance and enhance the efficacy of existing chemotherapeutic treatments.
The study found that the percentage of women receiving adjuvant chemotherapy who received taxanes such as paclitaxel increased more than sevenfold after early 1998, with rates rising in both node-positive and node-negative breast cancer. The authors suggest that publicity at ASCO and media coverage contributed to this shift.